M

MCB Clinical Research Centers | Colorado Springs, CO

Research site
(Unclaimed)
Location
110 S. Parkside Drive, Colorado Springs, Colorado, United States of America

Site insights

Top conditions

Top treatments

Dasotraline
SPN-812
Methylphenidate Hydrochloride
Aticaprant
SPD489
Pimavanserin
SPN-810
Lisdexamfetamine dimesylate
Dasotraline SEP360-105
OPC-64005

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 46 total trials

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Other: Placebo
Drug: Aticaprant

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling
Depressive Disorder, Major
Drug: Aticaprant

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling
Episodic Migraine
Drug: Atogepant
Drug: Placebo-Matching Atogepant
Locations recently updated

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 ER in pediatric ADHD patients

Active, not recruiting
Attention-Deficit/Hyperactivity Disorder
Drug: SPN-812

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

Trial sponsors

Sumitomo Pharma logo
AbbVie logo
Shire logo
Supernus Pharmaceuticals logo
Pfizer logo
Roche logo
Acadia Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Aerie Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems